CNTB Stock: Connect Biopharma Holdings Limited Stock Price, Analysis & Insights
Get live cntb stock price $2.12, comprehensive Connect Biopharma Holdings Limited stock analysis, charts, news, and expert forecast. Real-time cntb stock data and investment insights.
Loading chart...
Company Overview
Connect Biopharma Holdings Limited, a clinical-stage biopharmaceutical company, focuses on the discovery and development of immune modulators for the treatment of serious autoimmune diseases and inflammation. The company's lead product candidate is CBP-201, an anti-interleukin-4 receptor alpha antibody, which is in Phase IIb clinical trial for the treatment of inflammatory allergic diseases, such as atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps. Its products also comprise CBP-307, a small molecule modulator of sphingosine 1-phosphate receptor 1, a regulator of T cell mobilization out of lymph nodes into the periphery that is in Phase II for the treatment of autoimmune-related inflammation diseases; CBP-174, a small molecule histamine receptor 3 antagonist for oral administration, which is in a preclinical stage to treat chronic itch associated with skin inflammation; and CBP-233, a preclinical stage humanized antibody against interleukin-33, a cytokine involved in T helper 2 inflammation. The company was founded in 2012 and is headquartered in Taicang, China.
Company Information
- CEO
- Barry D. Quart
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 62
Contact Information
- Address
- East R&D Building
- Country
- CN
Investment Analysis & Business Insights
Investment Highlights
✓ Strong presence in the Healthcare sector with established market position
✓ Lower volatility stock (Beta: -0.13) may provide portfolio stability
Business Model & Strategy
Connect Biopharma Holdings Limited operates in the Biotechnology industry, focusing on medical services, pharmaceutical development, and healthcare delivery. Under the leadership of CEO Barry D. Quart, the company navigates Healthcare sector dynamics while pursuing growth opportunities. The Biotechnology model requires regulatory compliance, research investment, and patient outcomes to maintain competitiveness and drive shareholder value.
Market Position & Competitive Landscape
Connect Biopharma Holdings Limited competes in the Biotechnology within the broader Healthcare. With 118.5 million in market capitalization, the company is positioned as a emerging competitor in its sector. The Healthcare is characterized by demographic shifts, regulatory changes, and medical breakthroughs. As a publicly traded company on the NASDAQ Global Market, Connect Biopharma Holdings Limited provides investors with liquidity and transparency while subject to regulatory oversight. Investors evaluating Connect Biopharma Holdings Limited should consider industry-specific trends, competitive positioning, and Healthcare sector fundamentals.
Important Investment Considerations
- ⚠All investments carry risk, including potential loss of principal for Connect Biopharma Holdings Limited shareholders
- ⚠Market volatility can significantly impact stock price, especially for smaller companies
- ⚠Sector-specific risks in Healthcare may affect company performance
- ⚠Past performance does not guarantee future results for Connect Biopharma Holdings Limited
- ⚠Investors should consider how Connect Biopharma Holdings Limited fits within their overall portfolio allocation
- ⚠Valuation metrics suggest potential, but require fundamental analysis
Market Cap
118.51M
P/E Ratio
-2.38
Beta
-0.13
Investment Analysis & Insights
Key Investment Highlights
- Market Position: Healthcare leader with 118.51M market capitalization
- Trading Volume: 1.04M shares traded today
- Price Range: 52-week range of $0.51 - $2.86
- Exchange: Listed on NASDAQ Global Market
Financial Metrics
Market Analysis for Connect Biopharma Holdings Limited
Connect Biopharma Holdings Limited (CNTB) operates in the Biotechnology industry within the Healthcare sector. With a current market capitalization of 118.51M, the company represents a significant player in its market. The stock is currently trading at $2.12 with a positivedaily change of 26.19%.
The company's 62 employee base and presence on the NASDAQ Global Marketexchange position it as a Healthcare sector leader. Investors should consider the stock's P/E ratio of -2.38, beta of -0.13, and 52-week price range from $0.51 to $2.86when evaluating investment opportunities.
Why Invest in Connect Biopharma Holdings Limited?
Strengths
- • Established market presence in Healthcare
- • Strong financial metrics and market position
- • Listed on major exchange (NASDAQ Global Market)
- • Experienced leadership under Barry D. Quart
Investment Considerations
- • Monitor sector-specific market trends
- • Track quarterly earnings performance
- • Consider market volatility and beta
- • Evaluate long-term growth potential
Related Healthcare Stocks
About Healthcare Sector
The Healthcare sector includes companies that provide medical services, develop pharmaceuticals, manufacture medical devices, and offer health insurance.